

S 2543

Prescription Drug Pricing Reduction Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Sep 25, 2019

Current Status: Placed on Senate Legislative Calendar under General Orders. Calendar No. 225.

Latest Action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 225. (Sep 25, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/2543>

Sponsor

Name: Sen. Grassley, Chuck [R-IA]

Party: Republican • **State:** IA • **Chamber:** Senate

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Reported Original Measure	Sep 25, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 4199	Related bill	Jul 2, 2020: Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4228)
116 HR 5882	Related bill	Feb 12, 2020: Referred to the House Committee on Energy and Commerce.
116 HR 5281	Related bill	Dec 4, 2019: Referred to the Subcommittee on Health.
116 HR 4649	Related bill	Oct 30, 2019: Sponsor introductory remarks on measure. (CR H8607)
116 HR 1781	Related bill	Oct 29, 2019: Received in the Senate and Read twice and referred to the Committee on Finance.
116 HR 4629	Related bill	Oct 18, 2019: Sponsor introductory remarks on measure. (CR H8232)
116 S 1999	Related bill	Jun 27, 2019: Read twice and referred to the Committee on Finance.
116 HR 3029	Related bill	Jun 4, 2019: Subcommittee Hearings Held.
116 S 1505	Related bill	May 16, 2019: Read twice and referred to the Committee on Finance.
116 S 801	Related bill	Mar 14, 2019: Read twice and referred to the Committee on Finance.
116 HR 1264	Related bill	Feb 15, 2019: Referred to the Subcommittee on Health.

Summary (as of Sep 25, 2019)

Prescription Drug Pricing Reduction Act of 2019

This bill alters several programs and requirements relating to the prices of prescription drugs under Medicare and Medicaid.

Among other things, the bill

- requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for certain drugs covered under Medicare for which the average manufacturer price increases faster than inflation;
- requires drug manufacturers to issue rebates to the CMS for discarded amounts of certain single-dose drugs covered under Medicare, based on information reported by providers;
- reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit;
- requires the CMS to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to drug discounts and rebates, and payments between PBMs, health plans, and pharmacies;
- requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and
- increases the maximum rebate payable by drug manufacturers under the Medicaid Drug Rebate Program.

Actions Timeline

- **Sep 25, 2019:** Introduced in Senate
- **Sep 25, 2019:** Committee on Finance. Original measure reported to Senate by Senator Grassley. With written report No. 116-120.
- **Sep 25, 2019:** Placed on Senate Legislative Calendar under General Orders. Calendar No. 225.